Sunstone Life Science Ventures (Sunstone), a leading Nordic venture capital firm, is excited to announce its participation in a EUR 57 million Series A funding round for Kynexis B.V., a pioneering biotech company dedicated to advancing treatments for cognitive impairment associated with schizophrenia. Jacob Lange Moresco, Investment Director with Sunstone, will be joining Kynexis’ board of directors as part of this investment.

Press inquiries should be adressed to: